Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business

Executive Summary

Alder ended a patent dispute with Teva with a deal that will enable it to take its Phase III migraine candidate forward, while Sanofi restructures pair of partnerships with Alnylam and Regeneron heading into the J.P. Morgan Healthcare conference – where despite a flow of mid-stage deals, stakeholders are hoping US tax reform means bigger deals to come.

Advertisement

Related Content

Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond
Shire May Split Up – But Punting On Bigger Decisions For Now
Roche's Head Of Partnering On Deal Strategies And Aligning Attitudes
Roche Ramps Up Cancer Portfolio With $1.7bn Ignyta Buy
Sanofi Sees Cemiplimab As Path To Relevance In Immuno-Oncology
Incyte Adds PD-1 Inhibitor To Its Promising IDO With MacroGenics Deal
APOLLO Success Clears Alnylam For Lift-Off
Alnylam Hopes To Resume Fitusiran Dosing Quickly, Despite Unclear Cause Of Trial Death
TG Celebrates High Risk CLL Data - But Cloud Looms From Rival Trial
Alder Readies To Take On Teva, Others In Migraine

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC100175

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel